News

Friday
May, 24

AstraZeneca sues US over Medicare drug price negotiation plans

Featured in:



AstraZeneca said on Friday it has sued the US government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices.
The British drugmaker, which filed its complaint in a Delaware district court, joins other drugmakers and business groups claiming that the program would restrict the development of new medicines.
The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson, Merck & Co, Bristol Myers Squibb and privately-held Boehringer Ingelheim.
The drug price negotiation program is part of President Joe Biden‘s signature Inflation Reduction Act (IRA).
AstraZeneca said it was filing the legal challenge to “protect timely access to medicines for orphan indications” in the United States.
The US government offers several incentives to develop treatments that target orphan indications or rare conditions once they are launched in the market.
‍AstraZeneca said the program would deter continued development of treatments such as its cancer drug Lynparza and rare blood disorder drug Soliris, which carry orphan drug status for multiple conditions.
The US Department of Health and Human Services (HHS), which oversees the Medicare program for Americans aged 65 and older, is set to begin negotiations next month over 10 high-priced drugs, to be chosen by the agency unless it is blocked by a court.
An HHS spokesperson said in a statement that the agency “will vigorously defend the President’s drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities.”
The negotiated prices would take effect in 2026.





Source link

Find us on

Latest articles

- Advertisement - spot_imgspot_img

Related articles

Adani Enterprises shares in news today as firm to...

Adani Enterprises shares in news today as firm to consider raising of funds Adani Enterprises stock closed 8.01%...

PHD Marketing Takes Top Team to Drupa 2024

PHD Marketing Takes Top Team to Drupa 2024 Leading 360-degree B2B agency PHD Marketing is descending upon Düsseldorf...

Terinex Flexibles Opens Net Zero Co2 Rated Factory Building

Terinex Flexibles Opens Net Zero Co2 Rated Factory Building Terinex Flexibles is pleased to announce the opening of...

Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts...

Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers “As the widespread adoption of...

Celltrion receives European Commission approval of Omlyclo (CT-P39), the...

Celltrion receives European Commission approval of Omlyclo (CT-P39), the first and only omalizumab biosimilar approved in Europe The...

Publication of Definitive Interim Result of the Public Tender...

Publication of Definitive Interim Result of the Public Tender Offer – Constantia Holds 86.38% and Declares the...